World Health Organization (WHO) reported that a third of the world's populations develop latent tuberculosis infection (LTBI). Illicit drug users are at risk of suffering LTBI which potentially developing into active tuberculosis (TB). There is no gold standard diagnostic for LTBI and it is presumed that immune responses play an important role in LTBI. This study aimed o evaluate the ideal diagnostic tool to fill the absence of a gold standard and the effect of illicit drugs on the immune system. This was a cross sectional study conducted in illicit drug clinic, Methadone Maintenance Therapy (MMT) program of Dr. Moewardi Hospital, and MMT program of Puskesmas Manahan Surakarta, from February to March 2018. Total subjects were 24 respondents consisting of 5 respondents with TST (+) and 4 with T-SPOT.TB (+). We measured the agreement level of TST and T-SPOT.TB was moderate (k= 0.591, p= 0.003), the relationship of absolute cluster of differentiation 4 (CD4) to TST induration (r= 0.077, p= 0.719), the relationship between absolute CD4 and T-SPOT.TB spot-forming units (SFUs) ESAT-6 (r= -0.238, p= 0.262); CFP-10 (r= -0.117, p= 0.585); and the highest ESAT-6/CFP-10 (r= -0.033, p= 0.879). Tuberculin skin test and T-SPOT.TB have their own strengths and weaknesses, but in this study TST is slightly superior to T-SPOT.TB with moderate agreement level.
Introduction
Tuberculosis (TB) is the ninth cause of death in the world [1] . Tuberculosis is an infectious disease and is predicted to cause a high rate of latent TB infection (LTBI). Patients with LTBI have no sign or symptom of active and non-infectious TB but are at risk of becoming active TB [2] . A third of the world's population suffers from LTBI and 2-15% of patients can become active TB. The change of Latent TB infection into active TB is influenced by several factors, one of which is the main immune status. World health organization (WHO) recommends LTBI examination and treatment in risky populations, such as illegal drug/narcotics, psychotropic substances and other addictive substances (drugs) users [1, 3] .
The global burden of drug use is estimated to reach 185 million users. Extraordinary TB event cases have been reported in methadone treatment facilities in the United
States [4] . The result of a survey conducted by the National Narcotics Agency (BNN) and the University of Indonesia's Health Research Center (Puslitkes UI) showed that 1.9% of the drug prevalence in 2008 increased to 2.2% in 2011 and about 4 million Indonesians aged 10-60 years old are using drugs. The incidence of TB in drug users is 100 times higher than that in general population. Prevalence of LTBI among drug users is 10-59% [6] . Several in vivo and in vitro studies reported that drugs affect adversely the body's immune system thereby reducing the immune response or resulting in immunosuppression [7] .
The gold standard for LTBI diagnosis has not been available yet. Tuberculin skin tests (TST) have been used since more than 100 years ago and there has been no competitor until Interferon-Gamma Release Assays (IGRA) began to be introduced in early 2000 [8] . World Health Organization recommends in vivo immunodiagnostic examinations such as TST or in vitro examinations such as IGRA for LTBI diagnosis. Interferon-Gamma Release Assays examination includes, among others, T-SPOT TB (Oxford Immunotec).
Action mechanism of TST is to measure delayed-type hypersensitivity (DTH) cellular immunity against tuberculin purified protein derivative (PPD). T-SPOT.BT examination is an enzyme-linked immunospot test (ELISPOT) measuring the number of peripheral blood mononuclear cells producing INF-γ following the stimulation with early secretory antigen target 6 (ESAT-6) and culture filtrate protein 10 (CFP-10) [9] .
The objective of the current study was to evaluate the LTBI prevalence using TST and T-SPOT.TB among drug users. It also aimed to evaluate the sensitivity, specificity and suitability of T-SPOT.TB compared with those of TST. In addition, it was also intended to evaluate the relationship between absolute CD4 and TST and T-SPOT.TB among drug users. The results of TST and IGRA (T-SPOT.TB) research are important as an input for doctors and program managers, thus leading to the accuracy of LTBI diagnosis and treatment as well as the reducing TB burden and LTBI in Indonesia. DOI Drug users who meet the inclusion criteria were given education if available, and then they were asked to sign the informed consent. Data collected during the respondent's first visit included anamnesis, physical examination, and investigations, as well as respondents' characteristics such as age, gender, contact history, and the Bacille Calmette-Guérin (BCG) scar. Characteristics of drugs used were identified using WHO's alcohol, smoking and substance involvement screening test version 3.1 (ASSIST v3.1) to assess addiction, drug use length, and drug type [10] . Supporting examination included cluster of differentiation examination 4 (CD4), absolute T-SPOT.TB examination, and TST injection. The second visit was 48-72 hours later to interpret TST, and GeneXpert MTB/ RIF sputum examination was conducted with NaCl 3% nebulized sputum induction if the results were TST (+) and/ or T-SPOT.TB (+).
Tuberculin skin test
TST procedure was performed by injecting 0.1 milliliters (ml) of PPD RT23 2 tuberculin unit (TU) (serum statens institute, Copenhagen, Denmark) using Mantoux technique.
TST injection was carried out in the forearm volar surface area, far from the vein surface. Injection should be carried out with a single-use tuberculin gauge syringe No. 27
intradermally ( just below the skin surface) with a bevel needle facing up. The injection was carried out until a lump of 6-10 millimeters (mm) diameter appeared. 
GeneXpert MTB / RIF
GeneXpert MTB / RIF examination was carried out by sputum or by sputum induction with nebulization of NaCl 3%, and then sputum was collected into a sample tube with incubation for 15 minutes at room temperature. The sample was diluted into the cartridge using a pipette. The cartridge was inserted into the GeneXpert machine and the test was ready to begin. Interpretation of results was measured based on the fluorescence signal and algorithm calculation appearing on the monitor screen [13] .
Other laboratory tests
The measurement of absolute CD4 was carried out using the Becton Dickinson (BD)
FASCount System, USA. The BD FASCount system tool employed flow cytometry techniques. Flow cytometry uses light scattering, light excitation and emission principles of a fluorochrome molecule to generate specific multiparameter data from a particle and cell in 0.5 to 40 micrometers in diameter.
Statistical analysis
Data analysis was performed using SPSS 21 (IBM) for Windows. Basic data was pro- ICO-HELICS k ≤ 0.80, and optimal if 0.80 <k 00 1.00 [14] . The sensitivity and the specificity of T-SPOT.TB were presented in the 2x2 tabulation. The sensitivity and the specificity of T-SPOT.TB examination and the cut points were determined using the receiver operating characteristic (ROC) curve. The correlation test used was Pearson product moment (if it meets the requirements of normality) and Spearman's rank (if it does not meet the requirements of normality). The significance value is p <0.05 [15] .
Results
The respondents consisted of 30 drug users with 6 excluded respondents, so the total subjects of this study were 24 respondents. Six (25%) of respondents developed latent TB infection in this study, 5 (20.8%) respondents were TST (+) and 4 (16.7%) respondents were T-SPOT.TB (+). Three (12.5%) respondents were TST (+) and T-SPOT.TB (+),
(8.3%) respondents were TST (+) and T-SPOT.TB (-), 1 (4.2%) respondent was TST (-) and T-SPOT.TB (+), and 18 (75%) respondents were TST (-) and T-SPOT.TB (-). The flow of
research results can be seen in Figure 1 . 
The level of agreement between the T-SPOT.TB and the TST examinations in detecting LTBI on drug users
The kappa agreement level of T-SPOT.TB and TST is k= 0.591 with p= 0.003 (statistically significant). The agreement level of k= 0.591 is moderate (0.40 <k ≤ 0.60). The compatibility of TST to T-SPOT-TB in detecting LTBI among drug users is presented in Table   3 . Table 4 . 
ROC (receiver operator curve) of T-SPOT. TB
The receiver operating characteristic (ROC) curve is a way to determine the cut off point in a diagnostic test. The ROC curve is a graph illustrating the bargaining between sensitivity (ordinate Y) and specificity (ordinate X). The higher the sensitivity value, the lower is the specificity value and vice versa. ROC curve of T-SPOT.TB sensitivity and specificity can be seen in Figure 2 .
From the ROC curve, it can be seen that AUC of TSPOT.TB examination is 79.6% (95% CI 53.5% -100%) and p= 0.033 (statistically significant). The best diagnostic value of T-SPOT.TB examination based on the ROC curve is obtained at the intersection of 5 with a sensitivity value of 66.7%, and specificity of 100%. The cut-off point of the ROC analysis results on the T-SPOT.TB examination is presented in Table 5 . 
The relationship of absolute CD4 to TST and T-SPOT. TB examinations.
The mean TST induration is 5. Table 6 . Note: p = <0.05: significant; r: spearman's rho; n: ESAT-6 sample size: early secretory antigenic target-6; CFP: culture filtrate protein-10; SFUs: spot-forming units.
Discussion
This study shows that 25% of respondents were LTBI (+) (TST 20.8% and T-SPOT.TB 58.7% T-SPOT. TB [18] .
16.7%) and 75% of respondents were LTBI (-)
Factors likely affecting LTBI (+) in 25% of subjects in this study were age, contact history, BCG scar, absolute CD4 count, duration of the drugs used, and type of drugs used. Males developed more LTBI (23.8%) than females. The majority (87.5%) of respondents were in early adulthood (18-40 years old), with LTBI patients of 19.0%. World drug report in 2015 reported that there were more drug abusers in men than in women and in productive age [19] . Health Effort Building Division of Republic of Indonesia's Ministry of Health in 2010 reported more male drug users than male ones, with the highest prevalence in those aged between 15 and 44 years [5] . Considering the above data, the high number of male and productive age drug users is directly proportional to the incidence of LTBI.
There were 20.0% of LTBI (+) respondents with a history of contact with TB (at the same home) were; this figure was lower than those without history of contact; i.e., 26.3%. The high number of LTBI (+) respondents without a history of contact may be due to ignorance about TB disease among drug users so that they can be infected during jointly used narcotics equipment such as pipes, and while gathering in tight spaces or those with poor ventilation [20] . The higher LTBI (+) prevalence with TB contact is found in YungFeng Yen, et al.'s study (46.7%) [18] . Centers for Disease Control and Prevention (CDC) in 2005 reported the incidence of LTBI with TB contact history of 20-30 % [21] . Considering the data above, the history of contact corresponds to the CDC report. Immunity plays an important role in resisting Mtb infection, so not everyone with TB contact will be infected.
History of BCG immunization is found in 66.7% respondents with 18.8% TST (+) and
18.8% T-SPOT.TB (+). The history of BCG immunization does not affect the positive results
of TST and T-SPOT.TB examination, as confirmed by Yung-Feng Yen, et al's study reporting that positive TST was not associated with BCG scar [18] . The history of BCG vaccine, according to the CDC, is not a contraindication to TST; the effect of BCG vaccine decreases as time goes by, and if within 5 years after the BCG vaccine, a positive TST result is obtained, it is most likely due to Mtb [22] . The impact of BCG vaccine on TST specificity, according to WHO, depends on the vaccine strain used, the age at which the vaccine is given, and the dose given [3] . This study found that the BCG vaccine was given at infant time, so that the TST (+) results are actually positive rather than false positive.
Mean CD4 in the total respondents is 740.21 cells / uL while TST (+) is 705.80 cells / uL and T-SPOT.TB is 671.75 cells / uL. The drug users with LTBI (+) has a lower number of CD4 cells and it can be caused by drugs with immunosuppressive effect [23] . The population of drug users has a higher risk of becoming active TB. These data are appropriate for TB pathogenesis, where a decrease in the number of CD4 cells can attenuate the structure of the LTBI granuloma so that M. tuberculosis can replicate and go out of granulomas [22] . LTBI treatment can reduce the incidence of LTBI and prevent it from developing into active TB.
Severe drug addiction is at high risk of experiencing health, social, financial, legal, and relationship problems as a result of current patterns of substance use and tends to depend [10] . found that the longer the duration of drug use, the greater is the risk of developing LTBI [24] . Considering the data aforementioned, the duration of drug use tends to increase the incidence of LTBI.
The respondents in this study were 11 people in methadone maintenance therapy and 13 non-methadone active users with the same LTBI incidence rate, 27.3%. The substances used by the respondents of this study varied and on their way as drug users, they use not merely one substance. The result of WHO ASSIST's severe alcohol consumption is 54.2%, alcohol can change the innate immune response, so that the interaction between alcohol and Mtb will affect the number of cytokines, and then suppress TNF-α production [6] . 
The Agreement Level of TST and T-SPOT. TB Examinations in Detecting LTBI for Drug Users
The agreement level of T-SPOT.TB and TST examinations as a diagnostic tool for LTBI is 
Sensitivity and specificity of T-SPOT. TB and TST examination in detecting LTBI in drug users.
There has been no gold standard diagnostic tool for detecting LTBI. This inhibits the determination of TST and T-SPOT.TB examination sensitivity and specificity. Therefore, according to Rutjes AWS, et al., an alternative panel of experts or consensus can be used [27] . The World Health Organization, CDC, and Indonesian Pulmonologist Association (PDPI) state that both TST and IGRA (T-SPOT.TB) examinations can be used for LTBI diagnosis [1, 3, 22] . Researchers use TST as an alternative to the gold standard vacuum.
Grimes et al.'s study also used TST as a gold standard to assess the sensitivity and specificity of T-SPOT.TB [8] .
This study finds that sensitivity and specificity of T-SPOT.TB were 60.00% and 94.74%, respectively, better than the Grimes, et al.'s study that found the sensitivity of 50% and specificity of 79% [8] . The positive predictive value of T-SPOT.TB was 75.00% meaning that if the T-SPOT.TB (+) examination is possible, the patient will develop 75% of LTBI.
The negative predictive value of T-SPOT.TB is 90.00%, meaning that if the T-SPOT.TB (-) is checked, the probability of non-LTBI patients is 90.00%. The results of PLR and NLR for T-SPOT.TB examination are 11.40 and 0.42; it can be concluded that T-SPOT.TB has good diagnostic accuracy in detecting LTBI in drug addiction.
The results of the diagnostic test analysis based on the ROC curve can be obtained was not affected by absolute CD4 count. Considering the results, this study found no statistically significant relationship of absolute CD4 count to TST and T-SPOT.TB tests for detecting LTBI in drug dependent users.
Comprehensive analysis
This study found LTBI in 25% of respondents (TST [+] 20.8% and T-SPOT.TB [+] 16.7%).
Agreement level and T-SPOT.TB level are moderate (k= 0.591) and significant (p= 0.003).
The sensitivity of T-SPOT.TB is 60% and its specificity is high (94.74%), so that positive result indicates LTBI development. The relationship between absolute CD4 and TST examination is not statistically significant with positive correlation direction, whereas that between absolute CD4 and T-SPOT.TB is not statistically significant with negative correlation direction.
Research limitations
The limitation of this study is that there is no gold standard for diagnosing LTBI. The author determines the sensitivity and specificity of T-SPOT.TB with TST being a bridge to fill the gold standard void. Diagnostic test results cannot completely describe the accuracy of the T-SPOT.TB examination.
Conclusion
Tuberculin skin test and T-SPOT.TB have their own strengths and weaknesses but in this study, TST is slightly superior to T-SPOT.TB with moderate agreement level. There was no significant relationship between absolute CD4 and TST and T-SPOT.TB examinations in detecting LTBI in drug users.
Recommendation
There is no gold standard for diagnosing LTBI, so an agreement is needed or a new diagnostic tool should be invented as a gold standard. The availability and affordability of these two diagnostic tools can be considered as diagnostic standards. Government support is needed for some programs to find and to treat LTBI in high-risk populations (drugs users and others) to reduce TB burden and LTBI as a part of a strategy to achieve SDGs.
